

**Rezdiffra (resmetiron)**  
**Effective 01/01/2025**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Medical Benefit</b>	Phone: 833-895-2611	Fax: 888-656-6671
	<b>Pharmacy Benefit</b>	Phone: 800-711-4555	Fax: 844-403-1029
<b>Exceptions</b>	N/A		

### Overview

Rezdiffra (resmetiron) is a thyroid hormone receptor-beta (THR-beta) agonist indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

Rezdiffra should be avoided in patients with decompensated cirrhosis.

### Coverage Guidelines

If member is new to the plan (as evidenced by coverage effective date of less than or equal to 90 days), submission of medical records documenting that the member is currently receiving treatment with the requested drug, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

#### OR

Authorization may be granted when the following diagnosis-specific criteria is met:

1. Member has a diagnosis of metabolic dysfunction-associated steatohepatitis (MASH), also known as noncirrhotic nonalcoholic steatohepatitis (NASH)
2. Member has a diagnosis of F2 or F3 fibrosis
3. Member is 18 years of age or older
4. Requested medication is prescribed by or in consultation with a gastroenterologist or hepatologist
5. Member does not have any of the following:
  - a. Cirrhosis
  - b. Hepatocellular carcinoma
  - c. MELD score  $\geq$  12 (unless due to therapeutic anticoagulation)
  - d. Hepatic decompensation
  - e. Chronic liver disease other than MASH/NASH
  - f. Active autoimmune disease
  - g. ALT > 250 U/L
  - h. History of bariatric surgery
  - i. A1C  $\geq$  9%
  - j. Thyroid disease including active/untreated hypothyroidism (TSH > 7 IU/L with symptoms of hypothyroidism or > 10 IU/L without symptoms)

## **Continuation of Therapy**

Requests for reauthorization will be approved when the following criteria are met:

1. Documentation (e.g., medical records) demonstrating the member has had a positive clinical response to therapy

## **Limitations**

1. Initial and reauthorization approval will be granted for 12 months.

## **References**

1. American Association for the Study of Liver Diseases (AASLD). New MASLD nomenclature. AASLD Web site. June 2023. <https://www.aasld.org/new-masld-nomenclature>. Accessed March 15, 2024.
2. American Diabetes Association Professional Practice Committee. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes – 2024. *Diabetes Care*. 2024;47(Suppl 1):S1-S321. doi: 10.2337/dc24.
3. Andersson A, Kelly M, Imajo K, et al. Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis. *Clin Gastroenterol Hepatol*. 2022;20(11):2451-2461.e3. doi: 10.1016/j.cgh.2021.09.041.
4. Bernstein D, Kovalic AJ. Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease (NAFLD). *Metabol Open*. 2022;13:100158. doi: 10.1016/j.metop.2021.100158.
5. Cao YT, Xiang LL, Qi F, et al. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. *EClinicalMedicine*. 2022;51:101547. Doi:10.1016/j.eclinm.2022.101547.
6. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings co-sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract*. 2022;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.
7. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. *J Hepatol*. 2021;75(3):659-689. doi: 10.1016/j.jhep.2021.05.025.
8. EASL; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64(6):1388-1402.
9. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. *N Engl J Med*. 2024[a];390:497-509. doi: 10.1056/NEJMoa2309000.
10. Harrison SA, Ratzui V, Anstee QM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. *Aliment Pharmacol Ther*. 2024[b];59(1):51-63. doi: 10.1111/apt.17734.
11. Harrison SA, Taub, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. *Nat Med*. 2023;29(1):2919-2928. doi: 10.1038/s41591-023-02603-1.
12. Hatziagelaki E, Paschou SA, Schon M, et al. NAFLD and thyroid function: pathophysiologic and therapeutic considerations. *Trends Endocrinol Metab*. 2022;33(11):755-768. doi: 10.1016/j.tem.2022.08.001.
13. Institute for Clinical and Economic Review (ICER). Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH) (final evidence report). May 25, 2023. [https://icer.org/wp-content/uploads/2022/10/NASH-Final-Report\\_For-Publication\\_053023.pdf](https://icer.org/wp-content/uploads/2022/10/NASH-Final-Report_For-Publication_053023.pdf). Accessed March 15, 2024.



14. Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2021;161:1657-1669. doi: 10.1053/j.gastro.2021.07.049.
15. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005;41(6):1313-1321. doi: 10.1002/hep.20701.
16. Lim JK, Flamm SL, Singh S, et al. American Gastroenterological Association Institute Guideline on the role of elastography in the evaluation of liver fibrosis. *Gastroenterology*. 2017;152(6):1536-1543. doi: 10.1053/j.gastro.2017.03.017.
17. Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. *Gastroenterology*. 2022;163(3):764-774.e1. doi: 10.1053/j.gastro.2022.06.023.
18. Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. *Gastroenterology*. 2020;158(6):1822-1830. doi: 10.1053/j.gastro.2019.12.053.
19. Madrigal Pharmaceuticals. The resmetirom clinical development program: leading the way in NASH research. Madrigal Pharmaceuticals Web site. 2024. <https://www.madrigalpharma.com/our-programs/resmetirom/>. Accessed March 15, 2024.
20. Mostafa M, Abdelkader A, Evans JJ, Hagen CE, Hartley CP. Fatty liver disease: a practical approach. *Arch Pathol Lab Med*. 2020;144:62-70.
21. Portincasa P. NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. *Intern Emerg Med*. 2023;18(4):993-1006. doi: 10.1007/s11739-023-03203-0.
22. Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: definitions, risk factors, and workup. *Clin Liv Dis (Hoboken)*. 2012;1(4):99-103. doi: 10.1002/cld.81.
23. Rezdiffra (resmetirom) [prescribing information]. West Conshohocken, PA: Madrigal Pharmaceuticals, Inc.; March 2024.
24. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023(a);77(5):1797-1835. doi: 10.1097/HEP.0000000000000323.
25. Rinella ME, Lazarus JV, Ratziu V, et al for the NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *J Hepatol*. 2023(b);79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003.
26. Sangro P, de la Torre Alaez M, Sangro B, D'Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacologic treatment. *J Physiol Biochem*. 2023;79(4):869-879. doi: 10.1007/s13105-023-00954-4.
27. Tacke F, Puengel T, Loomba R, Friedman SL. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. *J Hepatol*. 2023;79(2):552-566. doi: 10.1016/j.jhep.2023.03.038.
28. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA Clinical Practice Update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. *Gastroenterology*. 2023;165(4):1080-1088. doi: 10.1053/j.gastro.2023.06.013.
29. Younossi AZ, Corey KE, Lim JK. AGA Clinical Practice Update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. *Gastroenterology*. 2021;160:912-918. doi: 10.1053/j.gastro.2020.11.051.

## Review History



10/09/2024 – Reviewed at October P&T. Effective 01/01/2025.

